GLP‑1 medications, explained

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. It is one of the signals that tells your body food has arrived. It nudges the pancreas to release insulin, quiets the release of glucagon (a hormone that raises blood sugar), slows digestion, and reduces hunger. The natural hormone breaks down within minutes.

A GLP-1 receptor agonist is a manufactured molecule that binds to the same receptors as that hormone and switches them on. The word agonist simply means it activates the receptor rather than blocking it. The important difference from the natural version is durability. These medications are engineered to resist rapid breakdown, so a single dose can keep working for a full day or, in the case of the weekly injections, for about a week.

Most of the well-known versions are given as an injection under the skin, using a small pen. Newer options come as a daily pill. Some of the latest agents, such as tirzepatide, activate a second hormone receptor called GIP alongside GLP-1, which is why they are sometimes described as dual agonists. The category keeps widening, but the shared idea is the same: borrow the body's own fullness signal and make it last.

The effect people notice first is on appetite. GLP-1 receptors sit in areas of the brain that govern hunger and fullness. When the medication activates them, meals feel satisfying sooner and the near-constant background chatter about food tends to fade. Many people describe this quieting as reduced food noise. You are not fighting hunger so much as feeling less of it.

The second effect is on the stomach. GLP-1 slows gastric emptying, meaning food moves out of the stomach more gradually. That prolongs the sense of fullness after a meal and blunts the sharp blood-sugar spike that normally follows eating. This slowing is also the reason nausea and early fullness are the most common side effects, especially in the first weeks.

The third effect is on blood sugar, and it is why these drugs began as diabetes treatments. GLP-1 prompts the pancreas to release insulin mainly when blood sugar is elevated, and it dials down glucagon at the same time. Because that insulin response is largely glucose-dependent, GLP-1 medications on their own rarely cause low blood sugar. That risk rises sharply when they are combined with insulin or sulfonylureas, which matters a great deal if you are also fasting. Our fasting guide covers that interaction in more depth.

The original and best-established use is type 2 diabetes. For many people with type 2 diabetes, these medications lower blood sugar effectively while also supporting weight loss, and several have been shown in trials to reduce the risk of heart and kidney complications. In diabetes care they are now a mainstay rather than a novelty.

The second major use is obesity, or overweight accompanied by a weight-related condition such as high blood pressure, sleep apnea, or high cholesterol. Here the medication is prescribed specifically for long-term weight management, alongside changes to eating and activity rather than instead of them. Approval criteria generally rest on body mass index plus these related health factors.

These medications are not suitable for everyone. They are not appropriate during pregnancy or when trying to conceive, and they are generally avoided in people with a personal or family history of medullary thyroid cancer or a rare condition called MEN 2. People with a history of pancreatitis or certain gastrointestinal conditions need careful evaluation. They are also not a treatment for type 1 diabetes. Only a clinician who knows your history can judge whether one of these drugs is a reasonable fit. This page is a primer, not medical advice; see our FAQ for related questions.

Semaglutide is the most familiar name. As a weekly injection it is sold as Ozempic for type 2 diabetes and as Wegovy for weight management. It has also long been available as a daily tablet, Rybelsus, for diabetes. In December 2025 the FDA approved an oral form of Wegovy, a once-daily semaglutide pill for weight loss that reached pharmacies in early 2026, making it the first GLP-1 pill cleared specifically for weight management. Like Rybelsus, the tablet is taken on an empty stomach with a short wait before eating.

Tirzepatide activates both the GLP-1 and GIP receptors. It is sold as Mounjaro for type 2 diabetes and as Zepbound for weight management, both as weekly injections. In trial data, including a head-to-head study against semaglutide, it has produced some of the largest average weight reductions seen in this class, though individual results vary widely.

Liraglutide is an older, shorter-acting option given as a daily injection, sold as Victoza for diabetes and Saxenda for weight loss. Lower-cost generic versions have become available, which keeps it relevant even as weekly drugs dominate attention.

The pill category expanded again in April 2026, when the FDA approved orforglipron, marketed as Foundayo. Unlike semaglutide, it is a non-peptide molecule, which means it can be taken any time of day without the food and water restrictions the semaglutide tablet requires. Its average weight loss in trials was more modest than the leading injections. Further options are moving through review: CagriSema, which pairs semaglutide with the amylin analogue cagrilintide, was submitted to the FDA in late 2025 but is not yet approved as of mid-2026, and retatrutide remains investigational. We track these developments in news.

The most common side effects are digestive: nausea, constipation, diarrhea, and a feeling of fullness that arrives quickly. These stem directly from slowed digestion and are usually strongest when starting the medication or moving to a higher dose. For many people they ease over several weeks as the body adjusts.

People tend to manage the day-to-day discomfort by eating smaller portions, slowing down at meals, favoring bland and lower-fat foods when nausea is present, and staying well hydrated. Because appetite and overall food and fluid intake often fall, and nausea, vomiting, or diarrhea can add fluid losses, dehydration is a genuine and often overlooked risk, so steady fluid intake matters. Gentle movement can help with constipation. Our nutrition guide goes deeper on eating patterns that tend to sit more comfortably.

There are more serious risks to know plainly. Rapid weight loss of any kind can cost lean muscle as well as fat, which is why resistance training and adequate protein matter; see fitness for that side. Rapid weight loss also raises the risk of gallstones. Rarer but serious concerns include pancreatitis, which usually announces itself as severe, persistent abdominal pain and warrants prompt medical attention. And the hypoglycemia risk mentioned earlier becomes real when these drugs are combined with insulin or sulfonylureas. Anyone combining medication with fasting should review that plan with a clinician first.

Almost everyone reaches a point where the scale stops moving, and this is normal rather than a sign of failure. A plateau usually reflects biology doing exactly what it evolved to do. As body weight falls, the body needs fewer calories to run, so the same eating pattern that once produced a deficit eventually matches the new, lower energy requirement. The gap closes, and weight settles.

A plateau can also mean you have reached the dose where the medication's appetite effect has leveled off, or simply that your body has arrived at a weight it will defend for a while. Clinicians sometimes adjust the treatment, but a stall is not automatically a cue to change anything. It is often a stable resting point.

What tends to help is shifting attention from the scale to the things that protect long-term health: keeping protein adequate, continuing strength work to preserve muscle, and holding steady rather than cutting harder. Eating too little to force the number down can backfire by accelerating muscle loss. A plateau is a good moment to check in with your clinician about whether your current approach is still serving you.

When the medication stops, its effects fade with it. The engineered molecule clears from the body over days to weeks, the appetite-quieting effect lifts, and hunger and food noise generally return to something closer to their former level. This is the pharmacology working as designed, not a personal shortcoming.

For that reason, research suggests many people regain a meaningful portion of the weight they lost after discontinuing, particularly without other support in place. Studies of semaglutide and tirzepatide have shown substantial regain in the year or so after stopping. This has reframed how clinicians describe these drugs: for obesity, they are increasingly understood as long-term treatments for a chronic condition, similar to blood-pressure medication, rather than a short course.

People stop for many valid reasons: side effects, cost, supply, pregnancy plans, or simply reaching a goal. If you are considering stopping, it is worth planning the transition with your clinician rather than quitting abruptly, and thinking about the eating, movement, and support habits that will carry forward. Stopping is a legitimate choice; going in with a plan tends to make it a smoother one.